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Abstract: Spirulina, now named Arthrospira, is a microscopic and filamentous 
cyanobacterium that has a long history of use as a safe food, lacking toxicity. It 
is commercially produced in large outdoor ponds under controlled conditions. 
The aim of this review article is to summarize the recent available information 
concerning the human clinical potential and applications of Spirulina, as well 
as clinical data related to the safety and side effects of Spirulina. Potential 
health benefits of Spirulina are mainly due to its chemical composition, which 
includes proteins (the highest protein content of any natural food, 55–70 %), 
carbohydrates, essential amino acids, minerals (especially iron), essential fatty 
acids, vitamins and pigments. In this respect, three major bioactive components 
of Spirulina, the protein phycocyanin (a biliprotein pigment), sulfated poly-
saccharides and gamma linolenic acid seem to play significant roles in impart-
ing improved human body functions. Furthermore, new experimental evidence 
supports the immunomodulation and antiviral effects of Spirulina supplemen-
tation. According to the Dietary Supplements Information Expert Committee of 
the United States Pharmacopeial Convention, the available clinical evidence 
does not indicate a serious risk to health or other public health concerns due to 
Spirulina. However, a few cases of severe side effects have been reported. 
Keywords: cyanobacterium; phycocyanin; phycocyanobilin; sulfated polysac-
charides. 
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1. INTRODUCTION 
Agriculture is faced with multiple challenges in the 21st century: i) increase 
in food production for a growing world population, which is expected to increase 
by about 2.3 billion people over the next 40 years, mostly in developing coun-
tries, ii) insufficient fresh water supply together with land degradation, which 
causes losses in agricultural productivity, iii) increase of the production of feed-
stock for bioenergy, iv) adoption of more efficient and sustainable production 
methods and v) adaptation to climate change.1,2. Furthermore, it is presently ac-
cepted that malnutrition is a silent massacre. According to United Nations 
sources, millions of children every year die either from malnutrition or are vic-
tims of malnutrition and micronutrient deficiency – the lack of key vitamins and 
minerals – with severe consequences on their physical and intellectual develop-
ment.3,4 Moreover, both overweight and underweight people may suffer either 
from a deficiency or an excess of the intake of nutrients needed for healthy living.5 
Taking into account the above challenges, a future increase of the global 
production of food and food protein and a combat of malnutrition could be ad-
dressed through the development of non-traditional farm products by biotechno-
logical intervention. Such a solution seems today economically viable by sup-
porting the mass cultivation of microalgae rich in protein, vitamins and other 
functional nutrients known to benefit health. In this respect, Spirulina microalga 
seems to offer the perfect solution.  
Spirulina, now named Arthrospira, are microscopic photosynthetic and fila-
mentous cyanobacteria (blue–green algae) that have a long history of use as food. 
Cyanobacteria are believed to have evolved 3.5 billion years ago and they are the 
first group of bacteria that evolved that could fix atmospheric carbon dioxide into 
organic carbon compounds using water with the simultaneous evolution of oxy-
gen. Before Columbus, Mexicans (Aztecs) exploited this microorganism as hu-
man food, while presently the African Kanembou tribe in the Lake Chad area 
(Republic of Chad) employs it for the same purpose. The name Spirulina derives 
from the spiral or helical nature of its filaments. Arthrospira is the scientific 
name of a cyanobacteria genus comprising a whole group of edible cyanobacteria 
sold under the name Spirulina. Among the various Arthrospira species, A. pla-
tensis and A. maxima are the most important. Arthrospira trichomes (filaments), 
which contain cylindrical cells aligned together in spirals or in straight lines. 
These filaments have variable length (usually 100–200 μm) and a diameter close 
to 6–12 μm, but the cell dimensions, degree of coiling and length of filaments 
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vary with species. The cell organization of Spirulina is typical of a prokaryote 
gram-negative bacterium with a lack of membrane-bound organelles. The cell 
wall constitutes a weak envelope that is composed of a number of layers, mostly 
of a peptidoglycan and lipopolysaccharide nature. The Spirulina  cells have a 
number of inclusions, such as thylacoid membranes with phycobilisomes, carbo-
xysomes, ribosomes, DNA fibrils and gas vacuoles, as well as polyglycan, poly-
phosphate and cyanophycin granules.6–10 
Spirulina grows naturally in alkaline lakes but is commercially produced in 
large outdoor or greenhouse ponds under controlled conditions. Microalgal culti-
vation is based on a photosynthetic process using sunlight, nutrition elements and 
CO2 contained in a fresh water culture medium under a relatively high tempe-
rature (optimum temperature: 35–38 °C). Commercial culture of Spirulina is fol-
lowed by harvesting the biomass, drying and packaging.9,11 
World market evolution of Spirulina involves mainly dried Spirulina whole 
biomass used as a human health food supplement, assuming that its consumption 
may benefit, prevent, help, or cure common diseases and malnutrition. Other 
commercial products containing Spirulina biomass or Spirulina extracts or active 
ingredients include protein supplements in animal feed, products for the impro-
vement of pet health, natural colors for foods and cosmetics and purified biomo-
lecules for medicine and biotechnology.10 The objectives of this paper are to re-
view recent literature on various health and safety aspects of Spirulina food sup-
plements and their possible side effects. 
2. CHEMICAL COMPOSITION 
Chemical analysis of Spirulina showed that it is an excellent source of pro-
teins, vitamins, dietary minerals and pigments. The biochemical composition de-
pends upon the specific Arthrospira source, culture conditions and season of pro-
duction.9,10,12–14  
The protein content of Spirulina (50–70 % of the dry weight) exceeds that of 
meat, dried milk, eggs, soybeans or grains. Spirulina proteins are complete, since 
all the essential amino acids are present. The highest values for the essential 
amino acids are those for leucine, valine and isoleucine. When compared to 
standard alimentary proteins (from meat, eggs or milk), it is somewhat deficient 
in methionine, cysteine, and lysine, but is superior to all plant proteins including 
proteins from legumes.6,10,13 
Spirulina proteins with significant health effects are the phycobiliproteins 
phycocyanin C and allophycocyanin at an approximately 10:1 ratio, which are 
proteins with linear tetrapyrrole prosthetic groups (phycocyanobilin) that in their 
functional state are covalently linked to specific cysteine residues of the proteins 
and they form light-harvesting antenna complexes of the cyanobacteria. Spirulina 
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is the only food containing phycocyanins, which represent about 15–25 % of the 
dry biomass of the microalga.15,16  
Half of the total Spirulina lipids are fatty acids.12,14 A detailed analysis of 
Spirulina fatty acids showed the presence of essential fatty acids (mostly ω-6). 
The rare polyunsaturated fatty acid γ-linolenic acid (GLA) with putative medi-
cinal properties represents 10–20 % of the fatty acids in A. maxima, compared to 
49 % in A. platensis and can be considered one of the best known source of GLA 
after human milk and some little used vegetable oils such as evening primrose, 
borage, blackcurrant seed and hemp oil. 10 g of Spirulina provide over 100 mg of 
GLA (which corresponds to more than two capsules of evening primrose oil).9 
Other major fatty acids present are the unsaturated oleic and linoleic acids as well 
as the saturated palmitic acid, which forms more than 60 % of lipids in A. ma-
xima. Monogalactosyl- and sulfoquinovosyl-diacylglycerol as well as phospha-
tidylglycerol are the major Spirulina lipids (20–25 % each).17 It is important that 
sulfolipids from cyanobacteria are active against the AIDS virus.10,12 
Virtually all the assimilable Spirulina carbohydrates consist of polymers 
containing glucose. The major polymeric component in A. platensis is a branched 
polysaccharide, structurally similar to glycogen.6 High molecular weight anionic 
polysaccharides with antiviral and immunomodulating activities (see below) have 
been isolated from Spirulina.18 A sulfated polysaccharide fraction with antiviral 
action (calcium spirulan) was extensively purified and shown to be composed of 
rhamnose, 3-O-methylrhamnose (acofriose), 2,3-di-O-methylrhamnose, 3-O-me-
thylxylose, uronic acids and sulfates.19,20 Recently, an acidic polysaccharide 
fraction has also been isolated from A. platensis, which induces the synthesis of 
TNF-α in RAW macrophages.18 
Spirulina is claimed to be the richest whole-food source of provitamin A 
(β-carotene), with 20 g of Spirulina also fulfilling the significant body require-
ments of vitamins B1 (thiamine), B2 (riboflavin) and B3 (niacin).10,12,13,21 Its 
mineral content varies depending on the culture medium. The most interesting 
minerals in Spirulina are iron, calcium, phosphorus and potassium.10,12 The ana-
lytical data for the chemical composition of Spirulina are presented in Table I. 
Whole-genome sequences of several Spirulina strains have already appeared 
in the literature. A. platensis NIES-39 genome structure is estimated to be a 
single circular chromosome of 6.8 Mb, yielding 6,630 protein-coding genes, two 
sets of rRNA genes and 40 tRNA genes.22 Whole-genome sequencing of the 
Arthrospira PCC 8005 strain, which was selected by the European Space Agency 
(ESA) as a nutritional product and an oxygen producer of the Micro-Ecological 
Life Support System Alternative (MELiSSA) for long-term manned space mis-
sions, showed the presence of 6,279,260 bases with an average G+C content of 
44.7 %, 5,856 protein-coding sequences and 176 genes encoding RNA were also 
predicted.23 Recently, the draft whole-genome shotgun sequencing of A. maxima 
__________________________________________________________________________________________________________________________
2013 Copyright (CC) SCS
Available online at shd.org.rs/JSCS/  HEALTH ASPECTS OF Spirulina  399 
was obtained. The draft genome was approximately 6.0 Mb in total, with 5,690 
protein-coding sequences.24 
TABLE I. Analytical composition of Spirulina (Arthrospira) 
Component  Relative dry weight, %  Reference 
Proteins 50–70  12 
Carbohydrates 15–25  10,13 
Lipids 6–13  14 
Nucleic acids  4.2–6  12 
Iron 0.058–0.18  12 
Calcium 0.13–1.4  12 
Phosphorus 0.67–0.9  12 
Potassium 0.64–1.54  12 
Carotenoids 0.37–0.59  10,18 
Chlorophyll α 0.66–1.2  10,13,18 
Ash 3–11  9 
Moisture 4–9  9 
3. HEALTH ASPECTS 
Although historically Spirulina was used as a food component, it has been 
thoroughly investigated using in vitro and in vivo experiments, including cell and 
tissue culture, animal testing as well as human clinical trials, for its role in human 
health management. A huge number of publications in peer reviewed scientific 
journals and book chapters covering health aspects of Spirulina have appeared 
during the last three decades. These articles described experimental approaches 
involving whole cell Spirulina preparations, various cell extracts and purified 
biomolecules, aiming at elucidating the potential health benefits of the consump-
tion of this microalga, so far with exciting results. Potential health effects in-
cluded: immunomodulation, antioxidant, anticancer, antiviral and antibacterial 
activities, as well as positive effects against malnutrition, hyperlipidemia, diabe-
tes, obesity, inflammatory allergic reactions, heavy metal/chemical-induced toxi-
city, radiation damage and anemias.10,12,25–30 In this respect, the most promising 
active Spirulina constituents appeared to be the protein phycocyanin,30 sulfated 
polysaccharide fractions,18 GLA31 and certain sulfolipids.32 While these medi-
cinal claims may be based on experimental observations, more research is needed, 
especially with larger scale randomized studies in humans, in order to rate the 
effectiveness of Spirulina as a nutraceutical and source of potential pharmaceu-
ticals, and to understand the mechanisms of action of specific Spirulina biomole-
cules, their short-term and long-term effects, and the safety of their use in func-
tional foods. 
Available new information or data not covered by previous review articles 
concerning human clinical potential of Spirulina, and data related to the safety 
and side effects of Spirulina are summarized below. 
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3.1. Immunomodulation 
Forty volunteers of both sexes with an age of 50 years or older took a Spi-
rulina supplement (3 g per day) for 12 weeks. A steady increase in the average 
values of the mean corpuscular hemoglobin in subjects of both sexes was re-
corded. An increase of indoleamine 2,3-dioxygenase enzyme activity (a sign of 
immune function) and white blood cell count were also observed for the majority 
of subjects.33 
In a recent clinical trial involving two studies, a pilot study with 11 indi-
viduals and a double-blind placebo controlled study with 12 individuals, healthy 
volunteers supplemented their diet with 200 or 400 mg day–1, respectively, for 
seven days with Immulina® (a commercial extract of A. platensis, which is 
known to activate THP-1 monocytes and CD+ T cells in vitro and enhance 
immunological functions in mice). An enhancement of natural killer cell activity 
following administration of Immulina® was observed. Evidence was presented 
that Braun-type lipoproteins of the Spirulina commercial extract were respon-
sible for the major portion of the in vitro monocyte activation.34 
3.2. HIV-infected and undernourished patients 
In a randomized study to compare the effect of A. platensis vs. soybean as 
food supplements on insulin-resistant HIV-infected patients, 33 patients received 
19 g of supplement (Spirulina or soybean) daily for 8 weeks. It was concluded 
that the insulin sensitivity in HIV patients improved more when Spirulina rather 
than soybean was used as nutritional supplement.35 Furthermore, when HIV-in-
fected or HIV-negative undernourished children and HIV-infected adults were 
treated with Spirulina supplementation,  clinical improvement was always ob-
served, including weight increase, improvement of hematological parameters and 
decrease in the HIV viral load.36–39 
3.3. Clinical potential of phycocyanobilin 
The chromophore phycocyanobilin (PCB) of Spirulina, was found to strongly 
inhibit NADPH oxidase activity, since in mammalian cells it is reduced to phyco-
cyanorubin, a close homolog of bilirubin, which shows a potent inhibitory acti-
vity of this enzyme complex (observed in nanomolar intracellular concentra-
tions). Due to the central roles of NADPH oxidase activation in pathology, PCB 
supplementation may induce prevention and therapy of various diseases in part 
mediated by NADPH oxidase overactivity in affected tissues. Medical conditions 
associated with or linked to NADPH oxidase activity include among others: car-
diovascular diseases, metabolic syndrome, diabetic complications, Parkinson's di-
sease, Alzheimer’s disease, rheumatoid arthritis, allergic reactions and cancer. 
Administration of PCB may be achieved by any desirable route including inges-
tion of whole Spirulina, phycocyanin protein or isolated tetrapyrrole chromo-
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phore. PCB represents about 4.7 % of the mass of phycocyanin. Thus, about 
0.66 % of the dry mass of Spirulina is PCB, or about 15 g of Spirulina can be 
expected to provide about 100 mg of PCB.40,41 
3.4. Safety aspects 
Spirulina is regulated as a food and as a dietary supplement.13 The Food and 
Drug Administration (FDA) of the USA has categorized several Arthrospira 
dried biomass products as “generally recognized as safe” (GRAS) for human 
consumption.42 Spirulina has typically been studied in daily doses of 1 to 10 g 
and a recommended dosage for adults is usually in the range of 3–10 g 
day–1.9,10,12 
The amount of iodine contained in 10 g of dried Spirulina biomass is only 3 
μg44 or less (not detected).44 Since the upper safe level for total daily intake of 
iodine (for a 60 kg bodyweight adult), established by the Scientific Committee on 
Food (SCF) and the European Food Safety Authority (EFSA), is 600 μg, while 
the corresponding value suggested by the US Institute of Medicine is 1100 μg,45 
there is no risk of a consumer taking in excessive iodine by Spirulina consump-
tion.  
Spirulina contains substantial amounts of several B12 analogues (corrinoid 
forms, pseudovitamin B12) which do not fulfill specific functional roles of vita-
min B12 for humans.46 However, vitamin B12 bioavailability experiments with 
animals fed with Spirulina showed that Spirulina intake does not interfere with 
mammalian B12 metabolism, thus showing that the B12 analogues do not present 
inhibitory actions.47 
Spirulina total nucleic acid contents of 4.2-6 % of microalga dry matter have 
been reported12 (the RNA content is about 3–4 times higher than that of DNA),6 
which are higher than those of animal meat and various plant foods,48 similar to 
those of unicellular algae but lower than those of bacteria and yeast.6 Dietary 
nucleic acids highly influence serum uric acid levels because of purine metabo-
lism. A maximum safe limit of RNA in the diet of 2 g day–1 has been sug-
gested48 since high levels of uric acid may result in pathological conditions.49 
Accordingly, a safety margin of 30 g maximum daily intake of Spirulina was re-
commended.49 
3.5. Side effects 
The Dietary Supplements Information Expert Committee (DSI-EC) reviewed 
recent information from human clinical trials, animal studies, and regulatory and 
pharmacopeial sources and analyzed adverse event reports regarding Spirulina to 
assess potential health concerns. The DSI-EC concluded that the available evi-
dence does not indicate a serious risk to health or other public health concerns 
and assigned a Class A safety rating for A. maxima and A. platensis, thereby 
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permitting the admission of quality monographs for these dietary supplement in-
gredients in the United States Pharmacopoeia and National Formulary.50 How-
ever, information is limited concerning interactions with pharmaceutical com-
pounds or other dietary supplements. A few side effects have been reported from 
the ingestion of Spirulina, including headache, stomach ache, muscle pain, flush-
ing of the face, sweating and concentration difficulties.51 A few cases of severe 
side-effects have also been reported, including hepatotoxicity52 and rhabdomyo-
lysis.51 Since Spirulina is an immunomodulatory supplement, it might affect di-
sease severity in patients with autoimmune diseases. These patients have to avoid 
the consumption of Spirulina.53,54 A case of anaphylaxis caused by the Spirulina 
pigment phycocyanin was also reported. Upon an oral challenge with increasing 
Spirulina doses, corresponding to four Spirulina tablets over a 3-h period, a 14-
old year adolescent experienced diarrhea and erythema.55 People with phenyl-
ketonuria should avoid the consumption of Spirulina.51 It has been suggested that 
Spirulina when present in the diet exerted a neuroprotective effect in a mouse 
model of amyotrophic lateral sclerosis (ALS), by retarding or stopping motor 
neuron degeneration.56 Nevertheless, as emphasized by the ALSUntangled 
Group,57 at this time there is no evidence that Spirulina is effective for ALS and 
there appears to be real and theoretical toxicities that patients with ALS may 
encounter with it. Until better efficacy and safety studies are published, the 
ALSUntangled Group does not support the use of Spirulina in patients with ALS.57  
It must be emphasized that the consumption of Spirulina of unknown origin 
or originating from countries that do not guarantee the quality and safety of the 
product should be avoided. The major areas of concern for the safe consumption 
of Spirulina are microbiological load, heavy metal content, pesticides, extraneous 
matter and cyanobacterial toxins.13,50 
4. CONCLUDING REMARKS 
Spirulina, a microscopic and filamentous cyanobacterium with widespread 
usage throughout the world as a dietary supplement and a potential solution for 
combating malnutrition, seems to offer significant health advantages to the con-
sumer. The positive effects of Spirulina in relation to its immunomodulation and 
antiviral properties are based on clinical evidence but larger trials are required. 
The microalga chromophore phycocyanobilin, as a potent inhibitor of NADPH 
oxidase, may have versatile potential in the prevention and therapy of various 
diseases mediated by overactivity of this enzyme. Spirulina is accepted as a safe 
food supplement and the total number of side effects reported in the literature is 
relatively small. The iodine and nucleic acid content of Spirulina do not pose 
health risks assuming a consumption of Spirulina of up to 30 g per day. 
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ИЗВОД 
ЗДРАВСТВЕНИ АСПЕКТИ МИКРОАЛГЕ Spirulina (Arthrospira) КАО ХРАНЉИВОГ 
СУПЛЕМЕНТА 
THEODORE G. SOTIROUDIS И GEORGIOS T. SOTIROUDIS 
Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 
48 Vassileos Constantinou Avenue, Athens 11635, Greece 
Спирулина (Spirulina), позната и као Артроспира (Arthrospira), је микроскопска фи-
ламентозна цијанобактерија која је дуго у употреби у исхрани. Комерцијално се произ-
води у великим отвореним базенима, у контролисаним условима. Циљ овог прегледног 
рада је да изнесе нове податке о клиничком потенцијалу и примени спирулине, као и о 
резултатима који се односе на безбедност и споредне ефекте. Потенцијалне здравствене 
благодети спирулине потичу од њеног хемијског састава, укључујући протеине (највећи 
садржај протеина од све природне хране, 55–70 %), угљене хидрате, есенцијане амино-
киселине,  минерале ( посебно  гвожђе),  есенцијалне  масне  киселине,  витамине  и  пиг-
менте. Три најважније компоненте спирулине које имају значајну улогу у побољшавању 
телесних функција код људи су протеин фикоцијанин, сулфати полисахарида и γ-лино-
ленска киселина. Нови експериментални докази упућују на закључак да спирулина има 
имуномодулаторне  и  антивирусне  ефекте.  Према  подацима  америчког  комитета 
(“Dietary Supplements Information Expert Committee of United States Pharmacopeial Conven-
tion”),  досадашње  клиничке  студије  не  указују  на  здравствени  ризик  услед  употребе 
спирулине, мада је пријављено неколико случајева са озбиљним пратећим појавама. 
(Примљено 20. октобра, ревидирано 18. децембра 2012) 
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